INKT MiNK Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1840229 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY10.8%
TTM EPS YoY25.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-95.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets297.2%
Debt / equity—
Current ratio0.97x
Interest coverage317.82x
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-33.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $5.76M | $6.34M |
| SG&A expense | $6.73M | $4.31M |
| Operating income | -$12.64M | -$11.29M |
| Interest expense | -$110,000 | -$93,000 |
| Net income | -$12.49M | -$10.78M |
| EBITDA | -$12.46M | -$11.07M |
| EPS (basic) | -2.93 | -2.86 |
| EPS (diluted) | -2.93 | -2.86 |
| Weighted avg. shares (diluted) | 4.27M | 3.77M |
| Banking | ||
| Net interest income | $180,246 | $172,568 |
| Balance sheet | ||
| Cash & equivalents | $13.36M | $4.58M |
| Current assets | $13.85M | $4.99M |
| PP&E, net | $390,869 | $732,929 |
| Total assets | $14.24M | $5.72M |
| Current liabilities | $13.03M | $6.96M |
| Total liabilities | $28.47M | $25.31M |
| Shareholders' equity | -$14.23M | -$19.59M |
| Shares outstanding | 4.71M | 3.96M |
| Cash flow statement | ||
| Operating cash flow | -$5.93M | -$9.56M |
| Financing cash flow | $14.72M | $10.82M |
| Depreciation & amortization | $181,745 | $215,437 |
| Stock-based compensation | $2.67M | $1.81M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.